Information  X 
Enter a valid email address

Company Name matching 'Santhera Pharmaceuticals Holdi'

Date
Time Source
Company
Announcement
15 Oct 2021 7:00 pm GNW   Santhera Pharmaceuticals Holdi Santhera Announces First Half-Year 2021 Financial Results and Updates on Corporate Progress
01 Oct 2021 6:00 am GNW   Santhera Pharmaceuticals Holdi Santhera will Publish its Interim Report for the First Half of 2021 on October 15, 2021
27 Sep 2021 6:05 am GNW   Santhera Pharmaceuticals Holdi ReveraGen and Santhera Announce FDA Orphan Grant Funding for Clinical Trial with Vamorolone in Becker Muscular Dystrophy
  6:00 am GNW   Santhera Pharmaceuticals Holdi Santhera Completes Subsequent Capital Increase for Financing Arrangements
23 Sep 2021 6:05 am GNW   Santhera Pharmaceuticals Holdi Santhera and ReveraGen to Present Phase 2a/2b Efficacy and New Safety Data with Vamorolone at Forthcoming Conferences
  6:00 am GNW   Santhera Pharmaceuticals Holdi Santhera Completes Capital Increase for Financing Arrangements
20 Sep 2021 6:00 am GNW   Santhera Pharmaceuticals Holdi Santhera Secures CHF 45 Million in Funding and Announces Preliminary First Half-Year 2021 Financial Results
24 Jun 2021 6:00 am GNW   Santhera Pharmaceuticals Holdi Santhera and ReveraGen to Present Findings from Pivotal VISION-DMD Study with Vamorolone at Parent Project Muscular Dystrophy 2021 Conference
23 Jun 2021 6:00 am GNW   Santhera Pharmaceuticals Holdi Santhera Announces Phase 4 LEROS Trial with Raxone® Met Primary Endpoint in Patients with Leber’s Hereditary Optic Neuropathy
22 Jun 2021 10:30 am GNW   Santhera Pharmaceuticals Holdi Santhera’s Shareholders Approve all Board Proposals at Today’s Annual General Meeting
01 Jun 2021 6:00 am GNW   Santhera Pharmaceuticals Holdi Santhera and ReveraGen Announce Positive and Statistically Highly Significant Topline Results with Vamorolone in Pivotal VISION-DMD Study
27 May 2021 6:00 am GNW   Santhera Pharmaceuticals Holdi Santhera Publishes Agenda for its Annual General Meeting
20 May 2021 6:00 am GNW   Santhera Pharmaceuticals Holdi Santhera Completes Capital Increase for Financing Arrangements
07 May 2021 6:00 am GNW   Santhera Pharmaceuticals Holdi Santhera Announces First Trading Day of New Convertible Bonds on SIX Swiss Exchange
04 May 2021 6:00 am GNW   Santhera Pharmaceuticals Holdi Santhera Announces Settlement of Exchange Offer and Issuance of New Senior Unsecured Convertible Bonds due 2024
03 May 2021 6:00 am GNW   Santhera Pharmaceuticals Holdi Santhera Announces Settlement of Convertible Bond Exchange Offer on May 4, 2021
30 Apr 2021 4:45 pm GNW   Santhera Pharmaceuticals Holdi Santhera Completes Capital Increases for Financing Arrangements
29 Apr 2021 6:00 am GNW   Santhera Pharmaceuticals Holdi Santhera Reports 2020 Annual Results
28 Apr 2021 6:00 am GNW   Santhera Pharmaceuticals Holdi Santhera and ReveraGen Announce New 2.5-year Treatment Data with Vamorolone in Duchenne Muscular Dystrophy
27 Apr 2021 7:15 pm GNW   Santhera Pharmaceuticals Holdi Santhera Reports End Results on Convertible Bond Exchange Offer
23 Apr 2021 5:05 pm GNW   Santhera Pharmaceuticals Holdi Santhera to Announce 2020 Results on April 29, 2021
20 Apr 2021 6:00 am GNW   Santhera Pharmaceuticals Holdi Santhera Reports Interim Results on Convertible Bond Exchange Offer
06 Apr 2021 6:00 am GNW   Santhera Pharmaceuticals Holdi Santhera Commences Convertible Bond Exchange Offer and Continues to Seek Votes on the Bondholders' Resolution
30 Mar 2021 6:00 am GNW   Santhera Pharmaceuticals Holdi Santhera Completes Capital Increase for Financing Arrangements
25 Mar 2021 6:00 am GNW   Santhera Pharmaceuticals Holdi Santhera Launches Exchange Offer for its CHF 60 Million Convertible Bonds
18 Mar 2021 4:45 pm GNW Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera’s Shareholders Approve all Board Proposals at Today’s Extraordinary General Meeting
10 Mar 2021 6:00 am GNW Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Completes Capital Increase for Financing Arrangements
09 Mar 2021 6:00 am GNW Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Announces Results of Bondholders’ Meeting
03 Mar 2021 6:00 am GNW Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Announces Completion of First 6-Month Period of Pivotal VISION-DMD Trial with Vamorolone in Duchenne Muscular Dystrophy
01 Mar 2021 6:00 am GNW Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Announces Positive Results with Lonodelestat in Early Phase Cystic Fibrosis Trial
24 Feb 2021 6:00 am GNW Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Calls Extraordinary General Meeting to Seek Approval for Proposed Strengthening of Capital Structure
16 Feb 2021 6:00 am GNW Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Announces Corporate Update and Proposal to Strengthen Capital Structure
05 Feb 2021 6:00 am GNW Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Completes Capital Increase for Financing Arrangements
25 Nov 2020 6:00 am GNW Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Completes Capital Increase for Financing Arrangements
17 Nov 2020 5:45 pm GNW Factsheet Santhera Pharmaceuticals Holdi (0QN1) ReveraGen Receives $3.3 Million NIH Commercialization Readiness Pilot Grant for NDA Preparations for Vamorolone in Duchenne Muscular Dystrophy
02 Nov 2020 6:00 am GNW Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Implements Reorganization and Secures Financing to Advance Vamorolone to Pivotal Read-out in Duchenne Muscular Dystrophy
22 Oct 2020 6:00 am GNW Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Completes Capital Increase for Financing Arrangements
06 Oct 2020 6:00 am GNW Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera to Discontinue Phase 3 SIDEROS Study and Development of Puldysa® in Duchenne Muscular Dystrophy (DMD) and Focus on Vamorolone
21 Aug 2018 6:00 am GNW Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera to Report First Half-Year Financial Figures and Provide Corporate Update on September 4, 2018
05 Jul 2018 6:00 am GNW Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera to Present Novel Data Highlighting the Clinical Relevance of Peak Expiratory Flow as Predictor of Disease Progression in Duchenne Muscular Dystrophy
22 Jun 2018 6:00 am GNW Factsheet Santhera Pharmaceuticals Holdi (0QN1) UK's MHRA renews Early Access to Medicines Scheme Scientific Opinion for Santhera's Raxone® (idebenone) in Duchenne Muscular Dystrophy
12 Jun 2018 6:00 am GNW Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Submits NDA in South Korea for Raxone® for the Treatment of LHON
12 Apr 2018 12:30 pm GNW Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera's Shareholders Approve all Board Proposals at Today's Annual General Meeting
05 Apr 2018 6:00 am GNW Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Announces Successful Completion of First Clinical Trial with Omigapil in Patients with Congenital Muscular Dystrophy
20 Mar 2018 6:00 am GNW Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Reports Solid Top-line Growth in 2017 and Reiterates its Strategy to Obtain Approval for Idebenone in Duchenne Muscular Dystrophy
05 Mar 2018 6:00 am GNW Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Reports Outcome of Exploratory Trial with Idebenone in PPMS Conducted at the NIH
22 Feb 2018 6:00 am GNW Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Completes Capital Increase to Settle Obtained License from Polyphor
15 Feb 2018 6:00 am GNW Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Obtains Worldwide Exclusive License from Polyphor to Develop and Commercialize Clinical Stage Candidate for Cystic Fibrosis and Other Pulmonary Diseases
06 Feb 2018 6:11 am GNW Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Launches U.S. Expanded Access Program with Idebenone for Patients with Duchenne Muscular Dystrophy (DMD)
29 Jan 2018 6:00 am GNW Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Reports Preliminary Key Financial Figures for 2017 and Provides Corporate Update
26 Jan 2018 6:00 am GNW Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Receives Negative CHMP Opinion on Appeal for Authorization of Raxone® in Duchenne Muscular Dystrophy
24 Jan 2018 12:35 pm GNW Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Anticipates Receiving a Negative CHMP Opinion on Appeal for Marketing Authorization Application for Raxone® in Duchenne Muscular Dystrophy
19 Jan 2018 6:00 am GNW Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Plans to Announce Regulatory Feedback for Raxone® in DMD and 2017 Preliminary Key Financial Figures
19 Dec 2017 6:00 am GNW Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Launches "Take a Breath DMD" Respiratory Disease Awareness Campaign for patients with Duchenne Muscular Dystrophy
06 Dec 2017 6:00 am GNW Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Pharmaceuticals, Summit Therapeutics, Catabasis Pharmaceuticals and Duchenne UK to host Duchenne Muscular Dystrophy Awareness Day
06 Nov 2017 7:37 pm GNW Factsheet Santhera Pharmaceuticals Holdi (0QN1) Todd Bazemore Steps Down from Role as Chief Operating Officer of Santhera's US Subsidiary
23 Oct 2017 6:00 am GNW Factsheet Santhera Pharmaceuticals Holdi (0QN1) First International Consensus Statement on the Clinical and Therapeutic Management of LHON published in the Journal of Neuro-Ophthalmology
03 Oct 2017 6:00 am GNW Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Presents Data and Hosts Symposium on Respiratory Function Decline in Duchenne Muscular Dystrophy at the World Muscle Society Congress
15 Sep 2017 6:00 am GNW Factsheet Santhera Pharmaceuticals Holdi (0QN1) Santhera Receives Negative Opinion from the CHMP for its Marketing Authorization Application for Raxone® in DMD and Intends to Appeal this Opinion


Company Announcements Archive »


a d v e r t i s e m e n t